Stock Financial Ratios

AKRX / Akorn, Inc. financial ratios include Market Cap, Enterprise Value, Book Value, Quick Ratio, Current Ratio, NCAV, EBITDA, Profit Margin, Operating Margin, Return on Invested Capital (ROIC), Return on Assets (ROA), Return on Equity (ROE), Piotroski F-Score, Altman Z-Score, Beneish M Score and Kaplan-Zingales KZ-Index.

Valuation Metrics
Market Cap ($M)4,155.19
Enterprise Value ($M)4,662.57
Book Value ($M)819.18
Book Value / Share6.51
Price / Book4.33
NCAV ($M)-468.73
NCAV / Share22.64
Price / NCAV-15.63
Income Statement (mra) ($M)
Net Income184.24
Balance Sheet (mrq) ($M)
Cash & Equivalents345.38
Cash / Share2.75
Quick Ratio2.91
Current Ratio3.91
Management Effectiveness (mra)
Return on Invested Capital (ROIC)0.11
Return on Assets (ROA)0.06
Return on Equity (ROE)0.22
Identifiers and Descriptors
Central Index Key (CIK)3116
Industry Groups
SIC 2834 - Pharmaceutical Preparations
Other Related CUSIPS
Share Statistics
Weighted Average Number Of Shares Outstanding Basic122,869,000
Weighted Average Number Of Diluted Shares Outstanding125,801,000
Weighted Average Number Diluted Shares Outstanding Adjustment2,932,000
Common Shares Outstanding124,415,759
Common Stock Shares Outstanding124,390,217
Scoring Models
Piotroski F-Score3.00
Altman Z ScoreN/A
Beneish M ScoreN/A
Kaplan-Zingales KZ-IndexN/A
Cash Conversion CycleN/A
Per Share Metrics
Preferred Stock Value Outstanding Per Share0.00
Assets Non Current Per Share0.00
Cash Per Share2.75
Accumulated Depreciation And Depletion Per Share0.00
Minority Interest Per Share0.00
Accounts Receivable Per Share1.50
Inventory Work In Progress Per Share0.00
Additional Paid In Capital Per Share0.00
Treasury Stock Per Share0.00
Accounts Payable Per Share0.00
Long Term Debt Per Share6.47
Assets Per Share16.33
Liabilities Per Share9.27
Debt Per Share6.47
Retained Earnings Per Share0.00
Liabilities And Stock Equity Per Share0.00
Assets Other Non Current Per Share0.00
Assets Current Per Share6.06
Intangibles Per Share0.00
Cash And Equivalents Per Share2.75
Goodwill Per Share0.00
Property Plant And Equipment Net Per Share0.00
Liabilities Current Per Share0.00
Equity Per Share7.05
Deferred Income Tax Liabilities Per Share0.00
Current Portion Of Long Term Debt Per Share0.00
Property Plant And Equipment Gross Per Share0.00
Property Plant And Equipment Per Share0.00
Inventory Raw Materials Per Share0.00
Inventory Per Share1.45
Assets Other Current Per Share0.00
Inventory Finished Goods Per Share0.00
Liabilities Other Non Current Per Share0.00

Peers - Pharmaceutical Preparations (2834)

Related News Stories

Fresenius: Proven Value Creation Amidst M&A Doubts

2018-01-20 seekingalpha
Shares of Fresenius trade at a discount to peers after the market has doubted the firm's M&A prowess in light of a troubled Akorn acquisition. (103-1)

Fresenius CFO backs acquisition course -Boersen-Zeitung

2018-01-07 reuters
FRANKFURT (Reuters) - German healthcare group Fresenius (FREG.DE) will continue to look for acquisitions even if that leads to a temporary rise in debt, Boersen-Zeitung quoted the company’s finance chief as saying. (19-1)

Akorn/Fresenius: Risky Arb

2017-11-02 seekingalpha
The strategic value of the deal to Fresenius still makes sense, but Fresenius will be taking on some real and reputational risks. (19-1)

Insys Founder Charged in Bribe Scheme Linked to Fentanyl-Based Painkiller - The New York Times

2017-10-27 nytimes
The billionaire founder of Insys Therapeutics was arrested on Thursday on federal charges that he participated in a scheme to bribe doctors to prescribe a fentanyl-based painkiller intended for cancer patients. (19-0)

Allergan settles with one of four companies contesting Restasis patent

2017-10-12 reuters
(Reuters) - Allergan Plc said on Thursday it reached a settlement with InnoPharma Inc, one of the four generic drugmakers challenging the patents for its dry eye medication Restasis in federal court. (221-0)

CUSIP: 009728106